TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03971071
Drug: Erenumab 70 mg
Normalized name: Erenumab 70 mg/mL solution for injection
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab once every 4 weeks. Subcutaneous injection.
Study: NCT03971071
Drug: Erenumab 140 mg
Normalized name: Erenumab 140 mg/mL solution for injection
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab once every 4 weeks. Subcutaneous injection.
Study: NCT00408876
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00657878
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 5 IV day 1 every 21 days
Study: NCT00657878
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175 mg/m2 IV day 1 every 21 days
Study: NCT00657878
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosing and schedule according to Institutional guidelines
Study: NCT00657878
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 on days 1,8,15 every 28 days
Study: NCT04147715
Drug: S-648414
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT03221907
Drug: GLA5PR GLARS-NF1
Normalized name: insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pregabalin tablet
Study: NCT03221907
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin capsule
Study: NCT03221907
Drug: Pregabalin placebo
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet manufactured to mimic pregabalin capsule
Study: NCT04590404
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA-approved forms of nicotine replacement therapy for smoking cessation.
Study: NCT04590404
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA-approved smoking cessation medication.
Study: NCT04560790
Drug: BD111 Adult single group Dose
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
Study: NCT04147715
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for oral administration
Study: NCT04147715
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet for oral administration
Study: NCT02112903
Drug: Encapsulated vortioxetine IR tablet, 20 mg
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02112903
Drug: Vortioxetine MR capsule 20 mg (pH 5.5)
Normalized name: vortioxetine 5 MG
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02112903
Drug: Vortioxetine MR capsule 20 mg (pH 6.0)
Normalized name: vortioxetine 20 MG
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02112903
Drug: Vortioxetine MR capsule 20 mg (pH 7.0)
Normalized name: vortioxetine 20 MG
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04069169
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
Study: NCT04069169
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
Study: NCT03652376
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
Study: NCT01004081
Drug: BIIB021
Normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID orally for 28 days
Study: NCT01004081
Drug: BIIB021
Normalized name: BIIB021
DrugBank: BIIB021 (DB12359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIW orally for 28 days
Study: NCT01004081
Drug: exemestane (Aromasin)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily in tablet form for 28 days
Study: NCT03187080
Drug: Paravertebral block using local anesthetic
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of local anesthetic (0.25% bupivacaine) that is \*NOT\* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
Study: NCT00140556
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin week 1 and 5 of radiation
Study: NCT02905188
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
Study: NCT02905188
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
Study: NCT01721707
Drug: Latanoprost+Brinzolamide combination
Normalized name: Brinzolamide
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 drop in each eye, 1x/day, at 9PM
Study: NCT01721707
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop in each eye, 1x/day, at 9PM
Study: NCT00140556
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
Study: NCT00140556
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib daily during radiation
Study: NCT02891161
Drug: durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg Q4 weekly
Study: NCT02472977
Drug: Ulocuplumab
Normalized name: Ulocuplumab
DrugBank: Ulocuplumab (DB12018)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02472977
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03309150
Drug: Berzosertib
Normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.
Study: NCT04176705
Drug: Lidocaine Cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
Study: NCT04176705
Drug: Triamcinolone Acetonide Cream
Normalized name: Triamcinolone Acetonide Cream
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
Study: NCT04599062
Drug: Talimogene Laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene Laherparepvec
Study: NCT05385029
Drug: Thyroxine
Normalized name: Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment for hypothyroidism or hyperthyroidism
Study: NCT00447187
Drug: LX201
Normalized name: LX201
DrugBank: LX201 (DB04943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
Study: NCT04663269
Drug: 4mg PF Dexamethasone
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
Study: NCT03819101
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg
Study: NCT01696474
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01783925
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
Study: NCT03264352
Drug: Allisartan Isoproxil
Normalized name: Allisartan isoproxil
DrugBank: Allisartan isoproxil (DB18880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
Study: NCT03264352
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
Study: NCT02059733
Drug: 18F-DTBZ
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study: NCT01607671
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
Study: NCT02445391
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02445391
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03722173
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution
Study: NCT03722173
Drug: BI 894416
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01176344
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
Study: NCT00630695
Drug: Lanreotide LP 90
Normalized name: lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide LP 90
Study: NCT00630695
Drug: Placebo lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo
Study: NCT05419908
Drug: Fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04492722
Drug: Dapagliflozin 10 mg
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.
Study: NCT01360632
Drug: OPC-34712 + ADT
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Study: NCT02371967
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
Study: NCT02867020
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
Study: NCT02867020
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
Study: NCT02867020
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive prednisone 10mg/day.
Study: NCT01554397
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
Study: NCT04021563
Drug: SR419
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ascending single and multiple doses of SR419 orally
Study: NCT01988428
Drug: Ceftriaxone 2000 mg
Normalized name: ceftriaxone 2000 MG
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone 2000 mg
Study: NCT00141596
Drug: Furosemide 40 mg bd
Normalized name: furosemide 40 MG
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02032290
Drug: ticagrelor loading
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02032290
Drug: Clopidogrel loading
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00911859
Drug: Siltuximab11 mg/kg
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
Study: NCT00911859
Drug: Siltuximab 8.3 mg/kg or 11 mg/kg
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
Study: NCT00911859
Drug: Velcade (bortezomib)
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
Study: NCT00911859
Drug: Velcade (bortezomib)
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
Study: NCT00911859
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
Study: NCT00911859
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
Study: NCT00911859
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
Study: NCT00911859
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
Study: NCT00911859
Drug: Velcade (bortezomib)
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
Study: NCT00911859
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
Study: NCT00911859
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take prednisone 60 mg/m2 orally according to the package insert.
Study: NCT02926183
Drug: Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
Study: NCT04181996
Drug: Colchicine Oral Product
Normalized name: colchicine Oral Product
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive either placebo or colchicine
Study: NCT00864942
Drug: bendamustine and lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
Study: NCT00864942
Drug: BL-NHL
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
Study: NCT00864942
Drug: BLR-CLL
Normalized name: Ad-ISF35 transduced CLL B-cells
DrugBank: Ad-ISF35 (DB17181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
Study: NCT03727464
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol general anesthesia
Study: NCT03727464
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane general anesthesia
Study: NCT01070394
Drug: LDX Treatment
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
Study: NCT04230265
Drug: Fludarabine (Non-IMP)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion over 3 days
Study: NCT04230265
Drug: UniCAR02-T (IMP)
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of single dose
Study: NCT02653092
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01652118
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02653092
Drug: Intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653092
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653092
Drug: GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02019979
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
Study: NCT00525031
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
Study: NCT00525031
Drug: Pegylated Interferon Alpha-2b (PGI)
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
Study: NCT00538564
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg oral tablets taken 3 times a week for 2 months
Study: NCT00729924
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg orally every 12 hours for 7 days